1.
HIV-1 pol gene polymorphism and antiretroviral resistance mutations in treatment-naïve adult patients in French Guiana between 2006 and 2012
by Darcissac, Edith
AIDS research and human retroviruses, 2016, Vol.32 (ja), p.801-811
2.
Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, random...
by Cohen, Calvin J, Dr
The Lancet (British edition), 2011, Vol.378 (9787), p.229-237
3.
Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT...
by Perez-Molina, José A, PhD
The Lancet infectious diseases, 2015, Vol.15 (7), p.775-784
4.
Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcr...
by Arribas, José R, Dr
The Lancet infectious diseases, 2015, Vol.15 (7), p.785-792
5.
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial
by Molina, Jean-Michel, Dr, Prof
The Lancet (British edition), 2011, Vol.378 (9787), p.238-246
6.
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
by Margolis, David A
The Lancet (British edition), 2017, Vol.390 (10101), p.1499-1510
7.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration
by Sabin, Caroline A
The Lancet (British edition), 2008, Vol.371 (9622), p.1417-1426
8.
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
by Siliciano, Robert F
Nature medicine, 2008, Vol.14 (7), p.762-766
9.
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials
by Katlama, Christine
AIDS (London), 2009, Vol.23 (17), p.2289-2300
10.
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-...
by Cahn, Pedro, Dr
The Lancet infectious diseases, 2014, Vol.14 (7), p.572-580
11.
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomi...
by Eron, Joseph
The Lancet (British edition), 2006, Vol.368 (9534), p.476-482
12.
High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen
by SUNPATH, Henry
AIDS (London), 2012, Vol.26 (13), p.1679-1684
13.
Molecular characterisation of the pol gene of vertically transmitted HIV-1 strains in children with virological failure
by Karunaianantham, Ramesh
AIDS research and human retroviruses, 2022, Vol.38 (ja), p.491-496
14.
Meta‐analysis: the impact of oral anti‐viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B
by Singal, A. K.
Alimentary pharmacology & therapeutics, 2013, Vol.38 (2), p.98-106
15.
Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients
by Lundgren, J D
AIDS (London), 2008, Vol.22 (14), p.F17-F24
16.
Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial
by POZNIAK, Anton L
AIDS (London), 2010, Vol.24 (1), p.55-65
17.
Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor–Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance
by Demarest, James
AIDS research and human retroviruses, 2018, Vol.34 (4), p.343-346
18.
Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness
by BANGSBERG, David R
AIDS (London), 2006, Vol.20 (2), p.223-231
19.
Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies
by ANTA, Lourdes
AIDS (London), 2013, Vol.27 (1), p.81-85
20.
Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir
by LABARGA, Pablo
AIDS (London), 2009, Vol.23 (6), p.689-696
